Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses

[1]  C. B. Hare,et al.  No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. , 2015, Clinical Infectious Diseases.

[2]  Frederick Albert Matsen IV,et al.  Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. , 2015, The Journal of infectious diseases.

[3]  James Y. Dai,et al.  Tenofovir-based preexposure prophylaxis for HIV infection among African women. , 2015, The New England journal of medicine.

[4]  S. McCoy,et al.  Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. , 2015, The Lancet. Infectious diseases.

[5]  L. Montaner,et al.  The mucosal expression pattern of interferon‐ɛ in rhesus macaques , 2014, Journal of leukocyte biology.

[6]  W. Greene,et al.  Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides , 2014, Science Translational Medicine.

[7]  Sarah G. Crist,et al.  Effects of Tenofovir on Cytokines and Nucleotidases in HIV-1 Target Cells and the Mucosal Tissue Environment in the Female Reproductive Tract , 2014, Antimicrobial Agents and Chemotherapy.

[8]  E. Boritz,et al.  Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression , 2014, Nature.

[9]  A. Kashuba,et al.  Topical microbicides and HIV prevention in the female genital tract , 2014, Journal of clinical pharmacology.

[10]  A. Gettie,et al.  Sex Hormones Selectively Impact the Endocervical Mucosal Microenvironment: Implications for HIV Transmission , 2014, PloS one.

[11]  F. Uckun,et al.  Vaginal microbicides and their delivery platforms , 2014, Expert opinion on drug delivery.

[12]  K. Ronacher,et al.  Distinct cytokine patterns in semen influence local HIV shedding and HIV target cell activation. , 2014, The Journal of infectious diseases.

[13]  Marc M. Baum,et al.  Cultivated Vaginal Microbiomes Alter HIV-1 Infection and Antiretroviral Efficacy in Colonized Epithelial Multilayer Cultures , 2014, PloS one.

[14]  L. Giudice,et al.  Phenotype and Functionality of CD4+ and CD8+ T Cells in the Upper Reproductive Tract of Healthy Premenopausal Women , 2014, American journal of reproductive immunology.

[15]  H. Ding,et al.  Relative resistance of HIV-1 founder viruses to control by interferon-alpha , 2013, Retrovirology.

[16]  Benjamin K. Chen,et al.  Postintegration HIV-1 infection of cervical epithelial cells mediates contact-dependent productive infection of T cells. , 2013, The Journal of infectious diseases.

[17]  Jessica Prince,et al.  Selection bias at the heterosexual HIV-1 transmission bottleneck , 2013, Science.

[18]  M. Malim,et al.  Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection , 2013, Nature.

[19]  L. Picker,et al.  CD4+ T‐cell depletion in HIV infection: mechanisms of immunological failure , 2013, Immunological reviews.

[20]  Richard D Moore,et al.  Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy , 2013, AIDS.

[21]  Karthik V. Sarma,et al.  Clinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic review. , 2013, American journal of public health.

[22]  R. Cone,et al.  Vaginal concentrations of lactic acid potently inactivate HIV , 2013, The Journal of antimicrobial chemotherapy.

[23]  M. Altfeld,et al.  Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. , 2013, The Journal of infectious diseases.

[24]  F. Kirchhoff,et al.  HIV-1 Vpu Does Not Degrade Interferon Regulatory Factor 3 , 2013, Journal of Virology.

[25]  B. Reinhard,et al.  Interferon-Inducible Mechanism of Dendritic Cell-Mediated HIV-1 Dissemination Is Dependent on Siglec-1/CD169 , 2013, PLoS pathogens.

[26]  Feng Gao,et al.  Phenotypic properties of transmitted founder HIV-1 , 2013, Proceedings of the National Academy of Sciences.

[27]  J. Rossjohn,et al.  Interferon-ε Protects the Female Reproductive Tract from Viral and Bacterial Infection , 2013, Science.

[28]  T. Hallett,et al.  Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk , 2013, AIDS.

[29]  O. Schwartz,et al.  SAMHD1 Restricts HIV-1 Cell-to-Cell Transmission and Limits Immune Detection in Monocyte-Derived Dendritic Cells , 2012, Journal of Virology.

[30]  A. Telenti,et al.  Siglec-1 Is a Novel Dendritic Cell Receptor That Mediates HIV-1 Trans-Infection Through Recognition of Viral Membrane Gangliosides , 2012, PLoS biology.

[31]  Simon Yu,et al.  INTERFEROME v2.0: an updated database of annotated interferon-regulated genes , 2012, Nucleic Acids Res..

[32]  R. König,et al.  SAMHD1 restricts HIV-1 infection in resting CD4+ T cells , 2012, Nature Medicine.

[33]  M. Altfeld,et al.  Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. , 2012, The Journal of infectious diseases.

[34]  A. Iwasaki,et al.  Unique features of antiviral immune system of the vaginal mucosa. , 2012, Current opinion in immunology.

[35]  N. Nasr,et al.  HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. , 2012, Blood.

[36]  S. Day,et al.  Role of novel type I interferon epsilon in viral infection and mucosal immunity , 2012, Mucosal Immunology.

[37]  F. Plummer,et al.  The Microbiological Context of HIV Resistance: Vaginal Microbiota and Mucosal Inflammation at the Viral Point of Entry , 2012, International journal of inflammation.

[38]  Baek Kim,et al.  SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates , 2012, Nature Immunology.

[39]  P. Cahn,et al.  Preclinical and first-in-human phase I clinical evaluation of stampidine, a potent anti-HIV pharmaceutical drug candidate. , 2012 .

[40]  W. Greene,et al.  Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. , 2011, Cell host & microbe.

[41]  J. Baeten,et al.  Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples , 2011, AIDS.

[42]  W. Heneine,et al.  High Susceptibility to Repeated, Low-Dose, Vaginal SHIV Exposure Late in the Luteal Phase of the Menstrual Cycle of Pigtail Macaques , 2011, Journal of acquired immune deficiency syndromes.

[43]  Brigitte E. Sanders-Beer,et al.  Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus , 2011, Mucosal Immunology.

[44]  B. Sobhian,et al.  SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx , 2011, Nature.

[45]  M. Washburn,et al.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein , 2011, Nature.

[46]  Taha Taha,et al.  Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women , 2011, AIDS.

[47]  J. Fahey,et al.  Innate Immunity in the Human Female Reproductive Tract: Endocrine Regulation of Endogenous Antimicrobial Protection Against HIV and Other Sexually Transmitted Infections , 2011, American journal of reproductive immunology.

[48]  M. Wainberg.  AIDS: Drugs that prevent HIV infection , 2011, Nature.

[49]  S. Shiboski,et al.  Phase 2a Study Assessing Colonization Efficiency, Safety, and Acceptability of Lactobacillus crispatus CTV-05 in Women With Bacterial Vaginosis , 2010, Sexually transmitted diseases.

[50]  Gaurav D. Gaiha,et al.  Association of TRIM22 with the Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection , 2010, Journal of Virology.

[51]  Sheena McCormack,et al.  PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial , 2010, The Lancet.

[52]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[53]  C. Baxter,et al.  Preventing HIV infection in women: a global health imperative. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  Ian Sanne,et al.  The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa , 2010, AIDS.

[55]  Marc C. Johnson,et al.  Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells , 2009, Cell.

[56]  M. McElrath,et al.  Human Immunodeficiency Virus Type 1 Mediates Global Disruption of Innate Antiviral Signaling and Immune Defenses within Infected Cells , 2009, Journal of Virology.

[57]  Sarah S. Wilson,et al.  Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. , 2009, The Journal of infectious diseases.

[58]  Clare F. McCoy,et al.  Safety and Pharmacokinetics of Dapivirine Delivery From Matrix and Reservoir Intravaginal Rings to HIV-Negative Women , 2009, Journal of acquired immune deficiency syndromes.

[59]  H. Weiss,et al.  Herpes simplex virus type 2: a key role in HIV incidence. , 2009, AIDS.

[60]  J. Steiner,et al.  Antiretroviral medication adherence and the development of class-specific antiretroviral resistance , 2009, AIDS.

[61]  L. V. Van Bortel,et al.  Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. , 2009, AIDS research and human retroviruses.

[62]  S. Pambuccian,et al.  Glycerol monolaurate prevents mucosal SIV transmission , 2009, Nature.

[63]  B. Friedland,et al.  Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[64]  M. Malim,et al.  APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts , 2008, PLoS pathogens.

[65]  chin-hua wang,et al.  Effectiveness of Cellulose Sulfate Vaginal Gel for the Prevention of HIV Infection: Results of a Phase III Trial in Nigeria , 2008, PloS one.

[66]  J. Fahey,et al.  A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. , 2008, AIDS.

[67]  A. Adimora,et al.  Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies , 2008, AIDS.

[68]  Michel Alary,et al.  Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. , 2008, The New England journal of medicine.

[69]  Marc C. Johnson,et al.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. , 2008, Cell host & microbe.

[70]  P. Feldblum,et al.  SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in Nigeria , 2008, PloS one.

[71]  R. Roddy,et al.  SAVVY® (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Ghana , 2007, PloS one.

[72]  F. Kirchhoff,et al.  Semen-Derived Amyloid Fibrils Drastically Enhance HIV Infection , 2007, Cell.

[73]  M. Fanger,et al.  Effects of Menstrual Cycle Status and Gender on Human Neutrophil Phenotype , 2007, American journal of reproductive immunology.

[74]  S. Robertson,et al.  Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. , 2007, Molecular human reproduction.

[75]  M. Khan,et al.  Human Immunodeficiency Virus Type 1 Vif Inhibits Packaging and Antiviral Activity of a Degradation-Resistant APOBEC3G Variant , 2007, Journal of Virology.

[76]  K. Abel,et al.  Pegylated interferon‐α2a treatment of chronic SIV‐infected macaques , 2007, Journal of medical primatology.

[77]  C. Moore,et al.  Population Level Analysis of Human Immunodeficiency Virus Type 1 Hypermutation and Its Relationship with APOBEC3G and vif Genetic Variation , 2006, Journal of Virology.

[78]  Michael D. George,et al.  Viral Suppression and Immune Restoration in the Gastrointestinal Mucosa of Human Immunodeficiency Virus Type 1-Infected Patients Initiating Therapy during Primary or Chronic Infection , 2006, Journal of Virology.

[79]  J. Justman,et al.  Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women , 2006, AIDS.

[80]  T. Schaefer,et al.  Secretion of cytokines and chemokines by polarized human epithelial cells from the female reproductive tract. , 2005, Human reproduction.

[81]  L. Jermiin,et al.  Characterization of the type I interferon locus and identification of novel genes. , 2004, Genomics.

[82]  C. M. Owens,et al.  The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys , 2004, Nature.

[83]  N. Roberts,et al.  Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. , 2003, The Journal of infectious diseases.

[84]  W. Greene,et al.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. , 2003, Molecular cell.

[85]  D. Phillips,et al.  Carrageenan Formulation Prevents Macrophage Trafficking from Vagina: Implications for Microbicide Development1 , 2003, Biology of reproduction.

[86]  H. Rees,et al.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial , 2002, The Lancet.

[87]  Christopher J. Miller,et al.  Simian Immunodeficiency Virus Rapidly Penetrates the Cervicovaginal Mucosa after Intravaginal Inoculation and Infects Intraepithelial Dendritic Cells , 2000, Journal of Virology.

[88]  Douglas S Kwon,et al.  DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells , 2000, Cell.

[89]  J. Eron,et al.  Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1 , 1999, Antimicrobial Agents and Chemotherapy.

[90]  M. Tsuchiya,et al.  Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. , 1999, Biochemical and biophysical research communications.

[91]  U. Tamoufé,et al.  A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. , 1998, The New England journal of medicine.

[92]  A. Gettie,et al.  Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. , 1998, AIDS research and human retroviruses.

[93]  P. Marx,et al.  A genetic and viral load analysis of the simian immunodeficiency virus during the acute phase in macaques inoculated by the vaginal route. , 1998, AIDS research and human retroviruses.

[94]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[95]  D. Ho,et al.  Progesterone implants enhance SIV vaginal transmission and early virus load , 1996, Nature Medicine.

[96]  J. Fortney,et al.  A Dosing Study of Nonoxynol-9 and Genital Irritation , 1993, International journal of STD & AIDS.

[97]  D. Edmonds,et al.  HIV Infection in a Patient with Meyer-Rokitansky-Küster-Hauser Syndrome , 1992, Journal of the Royal Society of Medicine.

[98]  P. Marx,et al.  Mechanism of genital transmission of SIV: a hypothesis based on transmission studies and the location of SIV in the genital tract of chronically infected female rhesus macaques. , 1992, Journal of medical primatology.

[99]  O. Strannegard,et al.  Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. , 1991, AIDS research and human retroviruses.

[100]  Sarman Singh,et al.  Semen of HIV-1-infected individuals: local shedding of herpesviruses and reprogrammed cytokine network. , 2012, The Journal of infectious diseases.

[101]  C. Boucher,et al.  Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. , 2012, AIDS reviews.

[102]  J. Baeten,et al.  Use of hormonal contraceptives and risk of HIV-1 transmission : a prospective cohort study , 2011 .

[103]  Gaurav D. Gaiha,et al.  Association of TRIM 22 with the Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection , 2010 .

[104]  E Windisch,et al.  [South Africa]. , 1976, Osterreichische Krankenpflegezeitschrift.